Mast Group Launches New ESPLINE SARS-CoV-2 Lateral Flow Antigen Test
By HospiMedica International staff writers
Posted on 26 Nov 2020
Mast Group Ltd. (Liverpool, UK) has launched the new ESPLINE SARS-CoV-2 lateral flow antigen test for the detection of COVID-19.Posted on 26 Nov 2020
The ESPLINE SARS-CoV-2 is an immunochromographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab. The lateral flow test is to be used as an aid in the diagnosis of SARS-CoV-2 infection. ESPLINE SARS-CoV-2 is a cassette-style assay using a simple procedure without any special instruments. As a feature, the test kit utilizes several kinds of antibodies to capture protein insideSARS-CoV-2 and coloring method based on enzyme reaction to detect the antigen-antibody complex.
Image: ESPLINE SARS-CoV-2 lateral flow antigen test (Photo courtesy of Mast Group Ltd.)
The test kit shows test result within 30 minutes after the reaction begins (positive results: 10-30 minutes, negative results: 30 minutes). The ESPLINE SARS-CoV-2 lateral flow antigen test has a sensitivity of 80% and specificity of 100%.
Related Links:
Mast Group Ltd.
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Mechanical Baby Scale
seca 725
